Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock Rating Lowered by UBS Group

Posted by Tyrone Williams on Aug 8th, 2026

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) was downgraded by investment analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

A number of other brokerages have also weighed in on CHGCY. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

View Our Latest Research Report on CHGCY

Chugai Pharmaceutical Stock Performance

Shares of CHGCY opened at $21.66 on Thursday. The firm has a market cap of $71.29 billion, a P/E ratio of 23.54 and a beta of 0.60. Chugai Pharmaceutical has a 52 week low of $20.00 and a 52 week high of $34.84. The firm’s 50-day simple moving average is $22.70 and its 200 day simple moving average is $26.02.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.71%. The firm had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. As a group, equities analysts forecast that Chugai Pharmaceutical will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.